Coherus Oncology (CHRS) Inventory Average (2019 - 2026)

Coherus Oncology (CHRS) has 8 years of Inventory Average data on file, last reported at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory Average rose 3.52% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 3.52% YoY), and the FY2025 full-year result was $3.7 million, down 88.96% from the prior year.
• Inventory Average grew to $4.0 million in Q1 2026, from $2.6 million in the prior quarter.
• In the past five years, Inventory Average ranged from a high of $65.4 million in Q3 2023 to a low of $2.6 million in Q4 2025.
• A 5-year average of $34.6 million and a median of $34.3 million in 2022 frame the typical range for Inventory Average.
• Across the five-year window, Inventory Average jumped 119.92% in 2023 and slumped 94.02% in 2025, its largest moves.
• Tracing CHRS's Inventory Average over 5 years: stood at $33.3 million in 2022, then surged by 94.54% to $64.7 million in 2023, then slumped by 59.93% to $25.9 million in 2024, then slumped by 89.93% to $2.6 million in 2025, then jumped by 53.2% to $4.0 million in 2026.
• Business Quant data shows CHRS's Inventory Average at $4.0 million in Q1 2026, $2.6 million in Q4 2025, and $3.3 million in Q3 2025.